Ajouter aux favoris   Ajouter cette page à mon bookmark --- SOCIAL BOOKMARKING --- Digg Furl del.icio.us Netscape

Driven by demographic trends, such as an increasing aged population, the global ophthalmic pharmaceutical market is set to become a serious growth area experiencing a compound annual growth rate of 11.11 per cent to 2012. This report explains just how this market will experience growth over the medium term future. Also do you know what the drivers and restraints of the market are? This report not only reveals these, but also details what strategies can be used to maximize profits from the drivers and restraints.

The Ophthalmic pharmaceutical market is divided into six major diseases. These are:

* Glaucoma
* Age-related macular degeneration
* Dry eye syndrome
* Ocular allergy
* Ocular inflammation
* Ocular infection

In this report each one of these disease areas is examined in terms of market growth and revenue, current and future drug treatments, market analysis, and major companies involved.

According to the findings of this new 175+ page report, visiongain reveals that Glaucoma therapies are set to dominate the market over the forecast period (2007-2012), accounting for over 40 per cent of market revenues by 2012. Pfizer's product Xalatan, used to lower intraocular pressure to treat glaucoma, will generate blockbuster revenues in 2007, and continue to dominate the entire ophthalmic pharmaceutical market. However are there any others which can compete with this for market share or beat its dominance? This report answers that question, with an analysis of other players in the market.

- Do you know what the market values of these major therapeutic areas of the ophthalmic world market are?

The report provides in-depth market analysis upon these areas, and extensively identifies both prescription and OTC ophthalmic drugs by disease and product type. The study also assess' the challenges faced by ophthalmic companies, and what exciting market opportunities exist in this up- and-coming therapeutic area.

Why You Must Buy This Report:

This report features over 50 tables, 20 graphs and charts, news, insights, the latest developments and an in depth survey of the opthalmic market with up-to-date analysis. This report is a vital addition to gaining an understanding of this highly profitable market sector and will give your company 'the edge' on your competitors. You can not afford to be without this latest report from visiongain.

With an increasing aged population and unmet medical needs this market is set to grow rapidly, but by how much? This report will tell you. Brought together in one easy to read, easily digested format, this report will keep you fully informed and up-to-date on the global ophthalmic pharmaceutical market.

Key questions that this report answers:

* Which current or future therapies will drive the ophthalmic market?
* The key companies involved in the market and their analysis?
* What R&D opportunities exist for ‘new comers’?
* What are the current and future blockbusters within the ophthalmic industry?

Unique benefits to you when you order this report:

- Immediate access through our exclusive Reading Room
- You can access your report whichever country you are in without using harddrive space
- Primary research throughout. You will not find this information anywhere else
- Report stored in your reading room for ever
- Full searchable report when you buy the company or corporate editions
- Copies can be printed off for offline reading
- Packed with charts, analysis, figures, graphs and tables

Chapter 1: Executive Summary
1.1 The World Ophthalmics Market 2007
1.2 Introduction to Ophthalmics, 2007
1.3 Summary of Ophthalmics, 2007
1.3.1 The Top Three Selling Ophthalmic Drugs, 2006
1.3.2 The Top Three Ophthalmic Drugs Revenue Forecasts ($m), 2007-2012

Chapter 2: The World Ophthalmic Pharmaceutical Market
2.1 Ophthalmic Industry Segmentation
2.1.1 Defining Key Ophthalmic Diseases
2.1.2 Defining Surgical Equipment Area
2.1.3 Defining Vision Care
2.2 The Worldwide Ophthalmic Pharmaceutical Market, 2007-2012
2.3 An Overview of the Eye
2.3.1 Anatomy of the Human Eye
2.3.2 The Vision Process
2.4 The Leading Ophthalmic Disease Profiles:Description and Prevalence
2.4.1 The Four Stages of Diabetic Retinopathy
2.4.2 Age Related Macular Degeneration (AMD)
2.4.3 Cataract: Surgery Offers Best Treatment
2.4.4 Glaucoma
2.4.5 Prevalence of Major Ophthalmic Diseases
2.5 The Top 10 Major Selling Ophthalmic Drugs and Their Manufacturers, 2005
2.6 Key Companies in the Ophthalmic Pharmaceutical Market
2.7 Drivers for the Ophthalmic Market
2.7.1 Ageing Population Leads to Increased Vision Loss
2.7.2 New Drug Delivery Techniques
2.7.3 Back-of-the-Eye Therapy: Future Looks Promising
2.8 Restraints for the Ophthalmic Market
2.8.1 The Lack of Involvement of Key Pharma Companies
2.9 Strategic Options in the Ophthalmic Industry
2.10 The Economic Cost of Eye Diseases
2.11 Market Opportunities to Target

Chapter 3. The Worldwide Glaucoma Pharmaceuticals Market
3.1 An Introduction to Glaucoma: the Leading Cause of Blindness in the Ophthalmic Market
3.1.1 Normal Fluid Drainage in the Eye
3.1.2 The Main Causes of Glaucoma
3.1.3 Risk Factors for Glaucoma
3.2 Primary Open Angle Glaucoma: The Most Common Form
3.3 Closed Angle Glaucoma - Less Common
3.4 Secondary Glaucoma: Mild or Severe?
3.5 Normal Tension Glaucoma (NTG) - Optic Nerve Damage
3.6 Pigmentary Glaucoma Causes Increase in Eye Pressure
3.7 Current Glaucoma Drug Treatments Available
3.7.1 Drug Classes That Increase Aqueous Humour Outflow
3.7.2 Drugs Classes That Increase Aqueous Humour Production
3.7.3 Aqueous Humour Volume Reduction Via Hyperosmolars
3.8 Beta Blockers: The Primary Treatment for Glaucoma or Not?
3.8.1 Analysis of Beta Blocker Drugs
3.9 Prostaglandin Analogues the Leading Glaucoma Treatment
3.9.1 Glaucoma Dominance Due to the Success of Xalatan
3.9.2 Price Could Play a Major Role in Prostaglandins Success
3.10 Docosanoids as Novel Glaucoma Therapies
3.11 Miotics - Many Drugs Available
3.12 Carbonic Anhydrase Inhibitors - Limited Choice of Drugs
3.12.1 Trusopt
3.12.2 Azopt - The Latest CAI
3.13 Alpha Agonists - Limited Availability
3.14 Hyperosmolars - Uncommon Glaucoma Treatment
3.15 Combination Therapies - Future Looks Promising
3.16 Glaucoma Drugs Preferred Than Surgery
3.17 Glaucoma Worldwide Market: A Dormant Giant
3.18 Prostaglandins Treatment Lead the Glaucoma Market
3.19 Key Drivers in the Glaucoma Market
3.20 Some Restraints in the Glaucoma Market
3.21 The Top 10 Selling Glaucoma Drugs in 2005
3.22 Pfizer's Blockbuster dominates the Glaucoma Market
3.23 The World Market Share of Top 10 Selling Glaucoma Drugs, 2005
3.24 The Market Share of the Top 10 Selling Glaucoma Drugs by Company
3.25 Company Market Share (%) of the World Top 10 Selling Glaucoma Drugs, 2005
3.26 Glaucoma Pipeline Products, 2007
3.27 Glaucoma Market Opportunities: Door Wide Open

Chapter 4: Age Related Macular Degeneration (AMD) Pharmaceuticals Market
4.1 An Introduction to Wet and Dry AMD: The Cause of Vision Loss in the Senior Population
4.2 Risk Factors Associated with AMD
4.3 AMD Prevalence
4.3.1 Wet AMD Prevalence
4.3.2 Dry AMD Prevalence
4.4 Dry AMD: No Proven Treatments, Yet
4.5 Drug Treatments for Wet AMD
4.6 Current AMD Drug Therapies
4.7 Lucentis v Avastin - cost and dose but no clinical trial
4.8 Future Treatments for AMD
4.9 Drug Therapies in the AMD Market Provides Commercial Targets
4.10 Market Drivers in the AMD Market
4.11 Market Restraints in the AMD Market
4.12 Lucentis Revenues: An eye opener
4.13 The Worldwide AMD Drug Market
4.14 Pipeline Products in the AMD Market
4.15 AMD Market Opportunities: Many Targets to Hit

Chapter 5: Ocular Allergies Pharmaceuticals Market
5.1 An Introduction to Ocular Allergies
5.2 Seasonal & Perennial Allergic Conjunctivitis - Most Common Types
5.2.1 Seasonal Allergic Conjunctivitis - Manifestation of Hayfever
5.2.2 Perennial Allergic Conjunctivitis: Persistant
5.3 Giant Papillary Conjunctivitis - Inflammatory Disorder
5.4 Vernal Keratoconjunctivitis - the Recurring Disease
5.5 Atopic Keratoconjunctivitis - Year Round Disease
5.6 An Overview of Ocular Allergy Drug Treatments
5.7 Antihistamines (H1-Receptor Antagonists)
5.8 Mast Cell Stabilisers Have Slow Onset of Action
5.9 Topical NSAIDs Have High Adverse Effect Incidence
5.10 Corticosteroids - Long-term Use Dangerous
5.11 Long Lasting Dual/Multiple-Action Agents
5.12 The Deciding Factor Between Systemic and Topical Medications
5.13 Alcon's Patanol: Dominates the Ocular Allergy Market
5.14 Market Drivers in the Ocular Allergy Market
5.15 Market Restraints in the Ocular Allergy Market
5.16 The Ocular Allergy Worldwide Market: Alcon’s Patanol Dominates
5.17 Ocular Allergy Pipeline Products, 2007
5.18 Ocular Allergy Market Opportunities
5.19 The Future for Ocular Allergies

Chapter 6: Dry Eye Syndrome Pharmaceuticals Market
6.1 Introduction to Dry Eye Syndrome - Tear Film Disorder
6.2 The Causes of Dry Eye Syndrome is Associated With Aging
6.3 High-Risk Populations for Dry Eye Syndrome
6.4 An Overview of DES Drug Treatments
6.5 Drug Treatment of Dry Eye - Artificial Tears Remain 1st Choice
6.6 Low Viscosity Artificial Tears
6.7 Moderate Viscosity Artificial Tears
6.8 High Viscosity Artificial Tears
6.9 Gel Formulations - The Novel System
6.10 Lubricating Ointments - Uncommonly Used
6.11 Restasis: Only Prescription Eye Drop
6.12 Mechanism of Action of Restasis
6.13 Allergy or Dryness: The Argument Continues
6.14 DES Market Drivers
6.15 DES Market Restraints
6.16 The Dry Eye Worldwide Drug Market: Restasis Leads the Market
6.17 Pipeline Products in the Dry Eye Market
6.18 Secretagogues: New Treatment Perhaps?
6.19 DES Market Opportunities

Chapter 7: Ocular Infections Pharmaceuticals Market
7.1 An Introduction to Ocular Infections
7.2 Hordeolum - Most Common Eyelid Lesions in the US
7.2.1 External Hordeolum - Small Yellowish Spot
7.2.2 Internal Hordeolum - Very Severe
7.3 Blepharitis - Inflammation of the Eyelids
7.4 Introduction to Conjunctivitis - Pink Eye
7.5 Bacterial Conjunctivitis - The Self-Limited illness
7.6 Viral Conjunctivitis - Affects All Ages
7.7 Epidemic Keratoconjunctivitis - Highly Contagious
7.8 Pharyngoconjunctival Fever - Child Fever
7.9 Keratitis - The Corneal Infection
7.10 Herpes Simplex Keratitis - Common Human Infection
7.11 Bacterial Keratitis - Sight-Threatening Disease
7.12 Fungal Keratitis - Remains a Challenge
7.13 Acanthamoeba Keratitis - Parasite Invader
7.14 Ocular Infection Drug Treatments
7.15. Topical Antibiotics: Fluroquinolones
7.15.1 4th Generation Fluroquinolones: Potent and Beneficial Agents
7.15.2 Problems Associated With Fluroquinolones
7.15.3 Aminoglycosides: Alcon’s Tobrex Performs Well
7.15.4 Erythromycin - Protein Inhibitor
7.15.5 Bacitracin - The Drug of Choice
7.15.6 Polymyxin B Combinations - Potent Killer
7.16 Systemic Antibacterials
7.17 Antivirals - Choice Limited
7.18 Antifungals - Wide Range Available
7.19 Ocular Infection Market Drivers
7.20 Ocular Infection Market Restraints
7.21 The Worldwide Ocular Infection Drug Market:Vigamox Dominates
7.22 Ocular Infection Pipeline Products, 2007
7.23 Ocular Infection Market Opportunities

Chapter 8: Ocular Inflammatory Pharmaceuticals Market
8.1 Ocular Inflammatory Disorders: An Overview
8.2 Chalazion - Painless But Deadly
8.3 Uvetitis - Common Cause of Vision Loss in the Young
8.3.1 Anterior Uveitis - Most Symptomatic
8.3.2 Intermediate Uveitis - Associated with Decreased Vision
8.3.3 Posterior Uveitis - Similar to Intermediate Uveitis
8.4 Topical Corticosteroids Remains the Primary Ocular Anti-Inflammatory Therapy
8.5 Topical Corticosteroids Available on the 2007 Market
8.5.1 Topical Steroids with Maximum Efficacy
8.5.2 Topical Moderate-Strength Steroids
8.6 Corticosteroid Ointment Treatments
8.7 Oral Corticosteroids - Not Commonly Used
8.8 Topical NSAIDS - Stings on Treatment
8.9 COX-2 Inhibitors - Only One Remains
8.10 Ocular Inflammation Market Drivers
8.11 Ocular Inflammation Market Restraints
8.12 The Worldwide Ocular Inflammation Drug Market, 2007-2012
8.13 Ocular Inflammatory Pipeline Products, 2007
8.14 Ocular Inflammatory Market Opportunities

Chapter 9: Conclusion
9.1 The Ophthalmic Pharmaceutical Market is Headed for High Consistent Financial Growth

List of Tables
Table 1.1 Total Worldwide Pharmaceutical Ophthalmic Market Forecast ($bn), 2007-2012
Table 1.2 Top Three Selling Ophthalmic Drugs in 2006
Table 1.3 Xalatan Revenue Forecast ($m), 2007-2012
Table 1.4 Cosopt Revenue Forecast ($m), 2007-2012
Table 1.5 Lucentis Revenue Forecast ($m), 2007-2012
Table 2.1 Total Worldwide Pharmaceutical Ophthalmic Market Forecast ($bn), 2007-2012
Table 2.2 Worldwide Pharmaceutical Ophthalmic Market Forecast by Disease ($bn), 2007-2012
Table 2.3 Ophthalmic Disease Area Market Share (%), 2006, 2009 and 2012
Table 2.4 Prevalence of Cataract, AMD and Open Angle Glaucoma Among Adults 40 Years and Older in the US, 2004
Table 2.5 Prevalence of Diabetic Retinopathy Among Adults in the US, 2004
Table 2.6 Estimated Prevalence of Myopia and Hyperopia Among Adults in the US, 2006
Table 2.7 Revenues ($m) of the Top 10 Selling Ophthalmic Drugs, 2005
Table 2.8 Top 10 Selling Ophthalmic Drugs by Market Share (%), 2005
Table 2.9 Advantages and Disadvantages of Ophthalmic Drug Delivery Routes
Table 3.1 Current Beta Blockers used to treat Glaucoma, 2007
Table 3.2 Current Prostaglandins used to treat Glaucoma, 2007
Table 3.3 Current Miotics used to treat Glaucoma, 2007
Table 3.4 Current Carbonic Anhydrase Inhibitors used to treat Glaucoma, 2007
Table 3.5 Current Combination therapies used to treat Glaucoma, 2007
Table 3.6 Summary of Glaucoma drugs by Company, 2007
Table 3.7 Total World Glaucoma Drug by Treatment Class Market Forecast ($bn), 2007-2012
Table 3.8 Total World Glaucoma Drug by Treatment Class Market Share Forecast (%), 2007-2012
Table 3.9 Top 10 Selling ($m) Glaucoma Drugs by Company, 2005
Table 3.10 Market Share (%) of Top 10 Selling Glaucoma drugs, 2005
Table 3.11 Market Share (%) of Top 10 Selling Glaucoma Drugs by Company, 2005
Table 3.12 Glaucoma Pipeline Products, 2007
Table 4.1 The prevalence of wet AMD worldwide in 2006 and 2025
Table 4.2 The prevalence of dry AMD worldwide in 2006 and 2025
Table 4.3 Current Drug Treatments for Wet AMD, 2007
Table 4.4 Lucentis Revenue Forecast ($bn), 2007-2012
Table 4.5 Total Worldwide AMD Drug Market Forecast ($bn) 2007-2012
Table 4.6 Pipeline AMD Products, 2007
Table 5.1 Antihistamine Products
Table 5.2 Mast Cell Stabiliser Products
Table 5.3 Topical Corticosteroid Top Products
Table 5.4 Dual Action Products
Table 5.5 Summary of Products Used to Treat Ocular Allergies, 2007
Table 5.6 Total Worldwide Ocular Allergy Drug Market Forecast ($bn), 2007-2012
Table 5.7 Ocular Allergy Pipeline Products, 2007
Table 6.1 Low Viscosity Artificial Tear Products Available, 2007
Table 6.2 Moderate Viscosity Artificial Tear Products Available, 2007
Table 6.3 High Viscosity Artificial Tear Products Available, 2007
Table 6.4 Gel Formation Products Available, 2007
Table 6.5 Lubricating Ointment Products Available, 2007
Table 6.6 Summary of Available Drug Therapies Used to Treat Dry Eye Syndrome, 2007
Table 6.7 Total World Dry Eye Drug Market Revenue Forecast ($bn), 2007-2012
Table 7.1 List of Ocular Infections
Table 7.2 Systemic Antiviral Drug Products Available
Table 7.3 Antifungal Ophthalmic Drug Products
Table 7.4 Summary of Drug Products Available to Treat Ocular Infections
Table 7.5 Total World Ocular Infection Drug Market Revenue Forecast ($bn), 2007-2012
Table 7.6 Ocular Infection Product Pipeline, 2007
Table 8.1 Topical Corticosteroid Drugs Available
Table 8.2 Summary of Ocular Inflammatory Products
Table 8.3 Total World Ocular Inflammation Drug Market Revenue Forecast ($bn), 2007-2012
Table 8.4 Ocular Inflammation Pipeline Products, 2007

List of Graphs
Graph 1.1 Total World Ophthalmic Pharmaceutical Market Forecast ($bn), 2007-2012
Graph 2.1 Total World Ophthalmic Pharmaceutical Market Forecast ($bn), 2007-2012
Graph 2.2 Total World Ophthalmic Pharmaceutical Annual Growth Rate (%), 2007-2012
Graph 3.1 Glaucoma World Market Forecast ($bn), 2007-2012
Graph 3.2 Glaucoma World Market Growth (%), 2007-2012
Graph 4.1 The Prevalence of Three Major Causes of Blindness Among Adults 40 Years and Older in the US
Graph 4.2 Lucentis Revenue Forecast ($bn), 2007-2012
Graph 4.3 Lucentis Growth Forecast (%), 2007-2012
Graph 4.4 Total World AMD Market Revenue Forecast ($bn), 2007-2012
Graph 4.5 Total World AMD Market Growth Forecast (%), 2007-2012
Graph 5.1 Total World Ocular Allergy Market Revenue Forecast ($bn), 2007-2012
Graph 5.2 Total World Ocular Allergy Market Growth Forecast (%), 2007-2012
Graph 6.1 Total World Dry Eye Market Revenue Forecast ($bn), 2007-2012
Graph 6.2 Total World Dry Eye Market Growth Forecast (%), 2007-2012
Graph 7.1 Total World Ocular Infection Market Revenue Forecast ($bn), 2007-2012
Graph 7.2 Total World Ocular Infection Market Growth Forecast (%), 2007-2012
Graph 8.1 Total World Ocular Inflammation Market Revenue Forecast ($bn), 2007-2012
Graph 8.2 Total World Ocular Inflammation Market Growth Forecast (%), 2007-2012

List of Charts
Chart 2.1 Ophthalmic Disease Area Market Share (%), 2006
Chart 2.2 Ophthalmic Disease Area Market Share (%),2009
Chart 2.3 Ophthalmic Disease Area Market Share (%), 2012
Chart 2.4 Top 10 Selling Ophthalmic Drug Companies Market Share (%), 2005
Chart 3.1 Glaucoma Drug by Class Market Share (%), 2006
Chart 3.2 Glaucoma Drug by Class Market Share (%), 2009
Chart 3.3 Glaucoma Drug by Class Market Share (%), 2012
Chart 3.4 Market Share (%) of Top 10 Selling Glaucoma Drugs, 2005
Chart 3.5 Company Market Share (%) of Top 10 Selling Glaucoma Drugs, 2005
Chart 6.1 Causes of Dry Eye
Picture 2.1 Anatomy of the Human Eye